PEACE-1: Identifying Prognostic and Predictive Biomarkers for SOC Treatment of mCSPC

At the ESMO Congress 2024, Dr. Cedric Pobel from Institut Gustave Roussy offers an overview of the latest ancillary study of the PEACE-1 phase 3 trial, including how immunohistochemistry was used to identify five phenotypes of mCSPC associated with radiographic progression-free survival and overall survival as a result of abiraterone acetate/prednisone with docetaxel and androgen deprivation therapy.

This regimen was previously established as standard of care for these patients as a result of the initial readout of PEACE-1.